非转移性去势抵抗性前列腺癌的当前与新兴药物治疗综述
本文综述了非转移性去势抵抗性前列腺癌(M0CRPC)的定义、诊断与治疗,重点汇总了SPARTAN和PROSPER两项III期试验结果:在雄激素剥夺治疗(ADT)基础上加用阿帕他胺或恩杂鲁胺可显著改善无转移生存期。ARAMIS试验(达罗他胺)仍在进行中,可能成为另一选择。
要点
- ADT仍是M0CRPC的基础治疗。
- SPARTAN显示阿帕他胺+ADT较ADT+安慰剂显著延长MFS。
- PROSPER显示恩杂鲁胺+ADT较ADT单药显著延长MFS。
核心结论
- SPARTAN和PROSPER两项III期试验为历史上缺乏高级别证据的M0CRPC提供了有效治疗选择。
- 阿帕他胺已获FDA批准用于M0CRPC患者。
- 新型AR通路抑制剂为M0CRPC的进一步研究提供了基础。
研究设计与样本
- 本文为综述,回顾并总结了M0CRPC定义、诊断和治疗的当前文献。
- 重点介绍了近期III期试验结果。
主要发现
- SPARTAN试验中,阿帕他胺+ADT组的中位无转移生存期(MFS)为40.5个月,ADT+安慰剂组为16.2个月,阿帕他胺+ADT较ADT+安慰剂降低远处转移或死亡风险72%。
- PROSPER试验中,恩杂鲁胺+ADT组的中位MFS为36.6个月,ADT单药组为14.7个月,恩杂鲁胺+ADT较ADT单药降低发生转移性CRPC或死亡风险71%。
- ARAMIS试验(达罗他胺)仍在进行中。
关键数值与推荐
- M0CRPC在美国估计影响100,000名男性。
- SPARTAN:阿帕他胺+ADT组MFS 40.5个月 vs ADT+安慰剂组16.2个月,远处转移或死亡风险降低72%。
- PROSPER:恩杂鲁胺+ADT组MFS 36.6个月 vs ADT单药组14.7个月,转移性CRPC或死亡风险降低71%。
临床怎么用
- 对于M0CRPC患者,可考虑在ADT基础上加用阿帕他胺或恩杂鲁胺以改善无转移生存期。
- 阿帕他胺已获FDA批准用于M0CRPC,可作为治疗选择。
- 达罗他胺的ARAMIS试验仍在进行中,结果可能提供另一选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-metastatic castration resistant prostate cancer (M0CRPC) is a heterogenous disease state affecting an estimated 100,000 men in the United States. Development of more sensitive modalities for detection of metastasis has altered the landscape of advanced prostate cancer, but M0CRPC has remained a condition that previously lacked FDA-approved treatment. The emerging data on new generation Androgen Receptor (AR) pathway inhibitors should address this gap in the management of such patients. METHODS: We reviewed and summarized the current literature for the definition, diagnosis and treatment of M0CRPC. We highlight the results of recent Phase III trials that show significant impact on the outcomes of M0CRPC. RESULTS: Androgen deprivation therapy remains the foundation of therapy for M0CRPC. Recently published Phase III trials provided data on improved progression free survival when ADT is augmented with newer AR pathway inhibitors. The SPARTAN trial showed that metastasis-free survival (MFS) for patients treated with apalutamide plus ADT is 40.5 months compared to 16.2 months for patients who received standard ADT plus placebo, a 72% reduction in the risk of distant metastasis or death in apalutamide plus ADT compared to ADT plus placebo. The PROSPER trial demonstrated that MFS for patients treated with enzalutamide plus ADT was 36.6 months compared to 14.7 months for patients who received standard ADT only indicating a 71% reduction in the risk of developing metastatic CRPC or death compared to ADT alone. The ARAMIS trial on darolutamide, another AR pathway inhibitor, is also ongoing, and can potentially be another fitting option for M0CRPC. CONCLUSION: The recent Phase III trials SPARTAN and PROPSER demonstrate effective treatment options for the M0CRPC disease state that has historically lacked treatment from high level evidence. In particular, an FDA-approved treatment, Apalutamide, can finally be offered for M0CRPC patients. The newer AR pathway inhibitors should provide a basis for further investigation into treatments for M0CRPC.
引用
- Alpajaro SIR, Harris JAK, Evans CP, et al. Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies. Prostate Cancer Prostatic Dis. 2018. PMID: 30115959. doi:10.1038/s41391-018-0078-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。